Aptus Endosystems, a medical device company developing advanced technology for treating abdominal aortic aneurysms (AAA), announced the appointment of James R Tobin to its board of directors. Tobin headed Boston Scientific for 10 years and was responsible for that company’s significant growth during that period.
“Jim is widely recognised as a leading medical device executive who will bring a combination of strategic vision and business acumen to Aptus Endosystems,” said Alan Kaganov, chairman of the Aptus board. “He is a proven and skilled executive with broad experience in healthcare markets and will be invaluable to our efforts to transform and develop an emerging medical device company focused on endovascular aneurysm repair (EVAR).”
Tobin, 67, served as president and CEO of Boston Scientific from March 1999 to July 2009 when the company’s revenues grew from more than US$2 billion to over US$8 billion. During his tenure, Boston Scientific achieved a number of significant milestones including the successful launch of the Taxus, Express paclitaxel-eluting coronary stent system, numerous acquisitions and strategic alliances including the transformative acquisition of Guidant and the growth of Boston’s international business to more than 40% of the company’s annual revenues.
“The Aptus team is bringing elegant new ideas to the AAA space to address clinical needs that have to date been underserved,” commented Tobin. “The company’s devices promise to make it possible to treat a broader range of patients successfully with fewer late failures.”